Since its creation Koltsovo has been developing as a center of biotechnology, molecular biology and virology. For instance, Koltsovo’s Institute
Vector is one of two places in the world which is an official repository of
smallpox. The second smallpox store resides at the
Center for Disease Control and Prevention in
Atlanta,
Georgia, USA. The science-driven business of the Science town has always been nurtured by research conducted by Vector specialists. The first wave of commercialization of Vector developments took place in the 1990s and was sustained by the Vector director
Lev Sandakchiev. A number of research spin-offs were created at that period, including Vector-Medica, Vector-Best, Vector-Bialgam, ImDi, which are currently among the most prominent innovation enterprises in Koltsovo. The research conducted in Koltsovo includes vaccines against breast cancer, hepatitis A and A+B, therapeutic HIV Vaccine and vaccine against pandemic H1N1 influenza; test-systems for early diagnostics of cancer, infectious diseases, TORCH-infections,
zoonosis infections, hepatitis C, as well as deadly viruses such as Ebola, Marburg, Machupo, Lassa, dengue and yellow fever. Koltsovo also has a number of companies active in
functional food production, such as liquid probiotics with 100% content of bifidumbacteria, muesli enriched with probiotics, products based on pure extracts of pine and fir, different types of
food supplements. Not only virology and biotechnology in different aspects attract attention of researchers from Koltsovo. Koltsovo is a home to a large IT company Center of Financial Technologies, software developer for financial, healthcare and public sectors, known for its creation of the Russian payment system
Zolotaya Korona. Koltsovo has an infrastructure for science-driven business, including: • Innovation center Koltsovo, a non-for-profit organization established in 2000 in order to assist the start and development of local innovation business • Business-incubator Koltsovo, established in 2006, which rents offices to innovation start-ups on beneficial conditions • BioTechnopark Koltsovo, opened in 2011, is an area of 114 hectares aimed for location of production and R&D premises of biotech companies. The BioTechnopark Koltsovo shall launch a Joint usage center in September 2014 which will serve as a certification and production center for BioTech start-ups, as well as a location for classes of the new Master’s program on biotechnology, launched jointly by Vector and
Novosibirsk State University. In 2013 the
Ministry of Economic Development of the Russian Federation has adopted the creation of a joint BioPharma and IT cluster in
Novosibirsk region with the BioPharma centered in Koltsovo. In 2014 35 companies of Koltsovo, as well as biotech companies from
Akademgorodok and
Berdsk have created a non-profit partnership BioPharm as an instrument for fostering cooperation and interests protection. On September 16, 2019, an explosion occurred in a decontamination room on the fifth floor of a six-story building at the laboratory complex. At the time, the area was being renovated, and purportedly there were no biohazard substances in the room. Windows were blown out and one contractor was sent to intensive care at a hospital with severe burns. The lab management assured the World Health Organization that the smallpox repository had not been impacted by the event. However, in a worst-case scenario, this does not rule out the possibility that some form of pathogens might have been dispersed by the blast. ==Society and economy==